No price history available.
Key financial summary
Financials in SAR| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | SARm | 4,962 | 5,034 | 5,372 | 5,741 | 6,451 | 6,736 | N/A | N/A |
| Operating profit | SARm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net profit | SARm | 246 | 239 | 305 | 329 | 370 | 322 | N/A | N/A |
| EPS reported | SAR | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating cashflow per share | SAR | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Capex per share | SAR | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF per share | SAR | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Free cash flow | SARm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt | SARm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value equity | SARm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value per share | SAR | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Number of shares | m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| DPS (TTM paid) | SAR | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Financial summary
Financials in SAR| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/B LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/S LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/FCF LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/EBITDA LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/Sales LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Earnings Yield LTM | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Quality | |||||||||
| ROE | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| ROIC | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Sales | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Growth and momentum | |||||||||
| EPS Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Sales Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Income Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating Profit Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend and capital structure | |||||||||
| Dividend Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Payout Ratio | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Debt | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Debt/EBITDA | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EBIT/Net interest | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/market cap | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/Equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross debt/equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
Al-Dawaa Medical Services Company operates as a prominent pharmaceutical retail enterprise throughout the Kingdom of Saudi Arabia, conducting its business through distinct retail and wholesale divisions. The company provides a comprehensive selection of products, including pharmaceuticals, fragrances, beauty accessories, cosmetics, and other general healthcare items. Beyond its core sales operations, Al-Dawaa is actively involved in managing pharmacies, overseeing pharmaceutical warehouses, retailing medical equipment, offering land transportation for goods, managing self-storage facilities, and providing marketing services for external entities. It also serves as a pharmaceutical agent. The company connects with customers via an extensive network of 837 pharmacies, augmented by its online and wholesale distribution channels. Al-Dawaa Medical Services Company was established in 1991 and is based in Al Khobar, Saudi Arabia.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Al-Dawaa Medical Services Company (4163.SR)
No price history available.
Based on consensus from external analysts. Not Kvantra's opinion.
Al-Dawaa Medical Services Company operates as a prominent pharmaceutical retail enterprise throughout the Kingdom of Saudi Arabia, conducting its business through distinct retail and wholesale divisions. The company provides a comprehensive selection of products, including pharmaceuticals, fragrances, beauty accessories, cosmetics, and other general healthcare items. Beyond its core sales operations, Al-Dawaa is actively involved in managing pharmacies, overseeing pharmaceutical warehouses, retailing medical equipment, offering land transportation for goods, managing self-storage facilities, and providing marketing services for external entities. It also serves as a pharmaceutical agent. The company connects with customers via an extensive network of 837 pharmacies, augmented by its online and wholesale distribution channels. Al-Dawaa Medical Services Company was established in 1991 and is based in Al Khobar, Saudi Arabia.